II. Causes
III. History
- History of Sleepiness
- Comorbid significant medical conditions (e.g. Neurologic Disorders)
- Medications (including non-prescription items, supplements and Herbals)
- Alcohol and other Drugs of Abuse
- Mood and emotional stressors
- Lifestyle, night-time work hours, and sources of sleep deprivation
- Sleep habits (including Insomnia, snoring, and possible Sleep Apnea)
- Restless Leg Syndrome
IV. Screening: Significant Daytime Somnolence indicating additional evaluation
- Falling asleep while driving OR
- Epworth Sleepiness Scale >12
V. Differential Diagnosis
-
Insomnia (Disorder of Initiating and Maintaining Sleep or DIMS)
- Insomnia typically causes paradoxical daytime hyperarousal instead of Sleepiness
- Insomnia with excessive Daytime Sleepiness suggests comorbidity (e.g. Sleep Apnea)
VI. Labs
- Thyroid Function Tests
- Renal Function tests
- Serum Calcium
-
Arterial Blood Gas (ABG)
- Rule-out Hypercapnia
VII. Diagnostics: Sleep Study
- Step 1: Overnight Polysomnography evaluates for Sleep Apnea
- Positive: Treat Sleep Apnea
- Negative: Perform step 2 testing
- Step 2: Polysomnography evaluates Sleep Onset Latency (time to fall asleep)
- Multiple Sleep Latency Test (MSLT)
- Hypersomnolence with early onset REM Sleep diagnoses Narcolepsy without cateplexy
- Maintenance of Wakefullness Test (MWT)
- Assess waking performance in alertness-critical professions (e.g. drivers, pilots)
- Multiple Sleep Latency Test (MSLT)
VIII. Management: General
- Treat underlying cause (e.g. Sleep Deprivation, Sleep Apnea, Restless Legs Syndrome)
- Practice Sleep Hygiene and ensure adequate sleep time
IX. Management: Stimulant Medications
- See Narcolepsy for specific management
- Contraindications
- Untreated Sleep Apnea
- Other secondary causes not fully excluded
- Mild or unproven Hypersomnolence
- Recent vascular event (CVA, MI) or multiple Cardiovascular Risk Factors
- Arrhythmia
- Uncontrolled Hypertension
- Adverse Effects
- Indications
- Excessive Sleepiness despite appropriate Obstructive Sleep Apnea management with CPAP
- Daytime Sleepiness with Shift Work Disorder
- Other moderate to severe excessive Daytime Sleepiness
- First-line agents (controlled substance C-IV Agents)
- Modafinil (Provigil, generic, roughly $90/month in 2020)
- Best safety profile and lowest abuse potential of all stimulant agents
- Czeisler (2005) N Engl J Med 353(5): 476-86 [PubMed]
- Armodafinil (Nuvigil, generic, roughly $90/month in 2020)
- Solriamfetol (Sunosi, expensive at $700/month in 2020)
- Modafinil (Provigil, generic, roughly $90/month in 2020)
- Novel agents (non-controlled)
- Pitolisant (Wakix)
- Released in 2020 for Daytime Somnolence for Narcolepsy
- Active at CNS Histamine receptors and appears to be as effective as Modafinil
- However, very expensive ($11,400 per month) andf many Drug Interactions as well as QT Prolongation
- (2019) presc lett 27(1):6
- Pitolisant (Wakix)
- Other agents (higher risk of abuse or side effects)
- Dextroamphetamine (Dexedrine)
- Methylphenidate (Ritalin)
- Pemoline (Cylert)
- Risk of hepatotoxicity